Immune Biomarker Discovery Services

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Immune biomarkers have greatly contributed to our understanding of various aspects of the pathophysiology of different diseases. Recent advances in high throughput omic technologies, immunoassays, flow cytometry or various combinations, will lead to the unbiased development of robust biomarkers for disease diagnosis and treatment outcomes. The discovery of immune biomarkers has become an important part of Chimeric Antigen Receptor (CAR) T Cell therapy development and immune monitoring is becoming increasingly important for future personalized treatment options. Creative Biolabs offers a portfolio of comprehensive, reliable, and accurate biomarker discovery and assay development services by employing a range of immunologic monitoring strategies.

Biomarkers in Immuno-oncology

The evaluation of immune-oncology biomarkers and the application of biomarkers for immune monitoring are rapidly evolving fields driven by the clinical success of recently approved immune checkpoint inhibitor therapies. Identifying biomarkers that can predict the response to immune therapies will enable the selection of patients who are likely to benefit from immunotherapy treatment. Immune biomarkers can be divided into several categories: prognostic biomarkers, predictive biomarkers, pharmacodynamic (PD) biomarkers, pharmacokinetic (PK) biomarkers, and correlative or surrogate endpoints.

Prognostic Biomarkers

A prognostic marker is measured before treatment and identifies tumor-specific molecular or histopathological characteristics. The Immunocore is an example of a prognostic immune biomarker that quantitates the immune cell composition, specifically CD8⁺ and CD45RO⁺ T cells in the tumor microenvironment, and associates the resulting immune score with clinical survival endpoints. Creative Biolabs is proficient at Immunocore Assay development and procedure, from the bench to the data analysis. Moreover, the Neutrophil-to-lymphocyte Ratio (NLR) is a generalized measure of systemic inflammation and has been utilized as a prognostic measure in many noncancer disease states. Scientists at Creative Biolabs are experts in NLR calculation and are pleased to assist clients based on their requirements.

Predictive Biomarkers

A predictive biomarker is usually measured before treatment and provides information on the probability of response to a particular therapy. By leveraging the wealth of information that we have on predictive biomarker identification, Creative Biolabs offers a range of high-quality services for biomarker, including PD-1/PD-L1 expression analysis, Single-nucleotide Polymorphism (SNP) Analysis, Neoantigen Analysis, myeloid-derived suppressor cells, and immunosuppressive T cell population analysis.

PD Biomarkers

PD biomarkers are becoming increasingly valuable for assessing drug activity and target modulation in clinical trials. Creative Biolabs has developed an efficient strategy, which can identify the majority of upstream and downstream genes in the biological pathway and can be used for the identification and prioritization of PD biomarker evaluation.

PK Biomarkers

Pharmacokinetics is concerned with the accurate determination of the magnitude of the independent variable in pharmacology and therapeutics. Given its vital role throughout all the phases of drug discovery, PK biomarkers evaluation is highly needed. Creative Biolabs has a highly experienced team of scientists who are proficient at PK biomarker evaluation on the protein, DNA and RNA levels.

Correlative and Surrogate Endpoints Biomarkers

There are many potential roles for biomarkers in clinical research. Biomarkers are also useful in providing insights about whether an intervention has a detectable effect on a biological pathway, and thus might serve as endpoints in a proof-of-concept trial. The identification of immune biomarker surrogates for clinical endpoints is an area of ongoing research in clinical trial immune monitoring. Creative Biolabs has organized a staff of outstanding scientists who have engaged in the research of correlative and surrogate endpoints biomarkers for many years. To enable innovative correlative and surrogate endpoints biomarker discovery, we offer highly customized solutions.

Trust Creative Biolabs to develop an efficient solution for immune biomarker development. For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

Závadová, E.; et al. Immunoscore and its predictive value for colorectal cancer. Klinicka onkologie: casopis Ceske a Slovenske onkologicke spolecnosti. 2015, 28:4S82-5.